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Abbreviations
ATRA “all-trans” retinoic acid
CIS CisPlatin
DOXO Doxorubicin
EPI Epirubicin
Introduction
Osteosarcoma is the most common bone tumour in humans (Goorin et al., 1985) and, in
veterinary medicine, especially in dogs (Harley et al., 1994). This tumor originates from
undifferentiated mesenchymal cells during normal osteogenic processes. The role of ATRA
in the cell differentiation of normal epithelial tissues has been well demonstrated (Lippman
et al., 1987). Currently retinoids are also used in clinical practice as differentiative agents in
human leukaemias (Moore, 1967). However, information on the effects of retinoids on solid
tumors is limited. Telomerase, a ribonucleoproteic enzyme acting in the terminal site of the
Vet Res Commun (2008) 32 (Suppl 1):S267–S269
DOI 10.1007/s11259-008-9125-z
R. Ciarcia : S. Florio
Dipartimento di Strutture, Funzioni e Tecnologie Biologiche, Università di Napoli “Federico II”,
Napoli, Italy
C. Pagnini : F. Fiorito : S. Montagnaro : R. Russo
Dipartimento di Patologia e Sanità animale, Università di Napoli “Federico II”, Napoli, Italy
A. Pellicane
DVM, Veterinary practitioner, Trapani, Italy
R. Ciarcia (*)
Dipartimento di Strutture, Funzioni e Tecnologie Biologiche, Università di Napoli “Federico II”,
via Delpino 1, 80137 Napoli, Italy
e-mail: roberto.ciarcia@unina.it
chromosome (TTAGGG)n, plays a key role in the process of “cellular immortalization” and
is thus an important target for chemotherapy (Blackburn et al., 1991). Anthracyclines and
platinum derivatives are wide spectrum chemotherapics, largely used in therapy for solid
tumours but with severe adverse effects (Pacilio et al., 1998). In this study we evaluated the
chemosensitizing activity of ATRA on D17 canine osteosarcoma, in relation to
chemotherapeutic schemes based on anthracyclines and cisplatin. Specifically, we studied
the activity of these chemotherapeutic agents, used alone or in association with ATRA, on
telomerase activity, apoptosis and D17 cell viability.
Materials and methods
We used D17 canine osteosarcoma cell lines that were maintained in RPMI-1640 medium,
supplemented with 10% fetal bovine serum (FBS), L-glutamine and antibiotics (62.5 mg/ml
penicillin and 100 mg/ml streptomycin) and incubated at 37°C in a humidified atmosphere of
5% CO2. Cytotoxicity assay: Drug Cytotoxicity was assayed by means of the MTT (3–4,
5-dimethylthiazol-2-yl-2,5.diphenyl tetrazolium bromide; Sigma) assay. Apoptosis: In order
to detect oligonucleosomal DNA fragmentation, the Cell Death Detection ELISA Plus
(Roche Diagnostics, Milan, Italy) was used. Telomerase activity was evaluated by Telomeric
Repeat Amplification Protocol (TRAP) assay using the TeloTAGG Telomerase PCR
ELISAPLUS (Roche Diagnostics, Milan, Italy): This is a semiquantitative protocol that
employs telomere-mimetic oligonucleotide TS (5′ AATCCGTCGAGCAGAGTT) and
downstream amplification oligo CX (5′ CCCTTACCTTACCCTTACCCTAA) plays a key
role in the process of “cellular immortalization". Statistical Analysis: The results are presented
as mean ± SD of three independent experiments. One-way ANOVAwith Turkey’s post test
was performed using GraphPad InStat Version 3.00 for Windows 95 (GraphPad Software,
San Diego, California). An error probability with P<0.05 was selected as significant.
Results
The cytotoxic activity of chemotherapic drugs on D17 canine osteosarcoma cells was
evaluated by means of a concentration effect curve. After 48 hours of incubation at
concentrations between 0.1 and 100 µM of DOXO, EPI, CIS and ATRA, D17 cells were
found to be relatively insensitive to CIS and ATRA, while DOXO and EPI at a concentration
of 50 µM decreased cell viability by 43.5% (DOXO) and 49.2% (EPI). Addition of ATRA at
an equimolecular concentration was able to decrease anthracycline and cisplatin induced cell
viability. In fact the cell viability, respectively, shifted by a reduction of 43.5% (DOXO) to
61.1% (DOXO+ATRA) and from 49.2% (EPI) to 62.3% (EPI+ATRA) and from 10.1% (CIS)
to 43.7% (CIS+ATRA). Chemotherapeutic drugs used alone showed no effect on telomerase
activity while ATRA at a 0.5 µM concentration was significantly able to decrease this activity:
in fact the absorbance shifted from 1.1 to 0.31. Addition of ATRA, at an equimolecular
concentration, to chemotherapeutic drug-treated tumour cells decreased telomerase activity,
the absorbance shifted from 1.09 (DOXO) to 0.79 (DOXO+ATRA), from 1.16 (EPI) to 0.74
(EPI+ATRA) and from 0.82 (CIS) to 0.66 (CIS+ATRA). Both chemotherapeutic drugs either
used alone or in association with ATRA induced apoptosis. In fact, the percentage of
apoptotic cells shifted from 12.2% (DOXO) to 32.1% (DOXO+ATRA); from 11.5% (EPI) to
24.4% (EPI+ATRA) and from 11.8% (CIS) to 34.8% (CIS+ATRA).
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Discussion
Is known that Apoptosis is defined by a cascade of biochemical events leading to nuclear
fragmentation and cell death. The cytotoxic effect of most chemotherapeutic agents in vitro
and in vivo depends on the induction of apoptosis in susceptible tumour cells (Schmitt and
Lowe, 1999). Our data demonstrated that Doxorubicin, Epirubicin and Cisplatin induce
apoptosis in D17 canine osteosarcoma cells and that ATRA is probably able to
chemosensitise tumor cells to drug-induced apoptosis. Results reported in the present
study demonstrate down-regulation of telomerase activity in D17 treated with anthraci-
clyne, cisplatin and ATRA. Combination drug therapy has emerged as a leading-edge
concept for the treatment of cancer and the results reported herein suggest that ATRA could
have an important role in this strategy.
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